Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association's Scientific Sessions 2023

Company to hold investor event in conjunction with data presentation on November 12, 2023 BOSTON, Sept. 26, 2023 -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new...

Related Keywords

Boston ,Massachusetts ,United States ,Philadelphia ,Pennsylvania ,American ,Ashlea Kosikowski ,Jen Robinson ,American Heart Association ,Verve Therapeutics Inc ,Exchange Commission ,Nasdaq ,Editing Medicine Designed To Durably Inactivate ,Scientific Sessions ,Pharmacodynamic Effects ,Editing Medicine Designed ,Durably Inactivate ,Lipid Lowering Therapy ,Novel Mechanisms ,Verve Therapeutics ,Private Securities Litigation Reform Act ,Markets ,